Boston Scientific Corporation $BSX Shares Bought by Clearstead Advisors LLC

Clearstead Advisors LLC raised its stake in Boston Scientific Corporation (NYSE:BSX) by 127.8% in the 4th quarter, HoldingsChannel.com reports. The fund owned 20,486 shares of the medical equipment provider’s stock after purchasing an additional 11,492 shares during the period. Clearstead Advisors LLC’s holdings in Boston Scientific were worth $1,953,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Legal & General Group Plc raised its holdings in shares of Boston Scientific by 4.0% in the fourth quarter. Legal & General Group Plc now owns 10,876,617 shares of the medical equipment provider’s stock valued at $1,037,085,000 after buying an additional 419,442 shares during the last quarter. HBK Sorce Advisory LLC raised its holdings in shares of Boston Scientific by 2.7% in the fourth quarter. HBK Sorce Advisory LLC now owns 7,773 shares of the medical equipment provider’s stock valued at $741,000 after buying an additional 202 shares during the last quarter. Simplify Asset Management Inc. raised its holdings in shares of Boston Scientific by 92.3% in the fourth quarter. Simplify Asset Management Inc. now owns 15,551 shares of the medical equipment provider’s stock valued at $1,483,000 after buying an additional 7,464 shares during the last quarter. First National Trust Co raised its holdings in shares of Boston Scientific by 1.2% in the fourth quarter. First National Trust Co now owns 116,170 shares of the medical equipment provider’s stock valued at $11,077,000 after buying an additional 1,364 shares during the last quarter. Finally, William Blair Investment Management LLC purchased a new stake in shares of Boston Scientific in the fourth quarter valued at about $4,914,000. 89.07% of the stock is owned by hedge funds and other institutional investors.

Boston Scientific Trading Down 0.2%

NYSE BSX opened at $57.65 on Wednesday. The stock has a market capitalization of $85.68 billion, a P/E ratio of 24.12, a P/E/G ratio of 1.06 and a beta of 0.62. Boston Scientific Corporation has a 52-week low of $52.52 and a 52-week high of $109.50. The firm has a 50-day moving average price of $61.52 and a 200 day moving average price of $79.54. The company has a quick ratio of 1.22, a current ratio of 1.90 and a debt-to-equity ratio of 0.42.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.79 by $0.01. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The company had revenue of $5.20 billion during the quarter, compared to the consensus estimate of $5.19 billion. During the same period last year, the firm earned $0.75 EPS. The company’s revenue for the quarter was up 11.6% on a year-over-year basis. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Equities research analysts expect that Boston Scientific Corporation will post 3.38 EPS for the current year.

Boston Scientific announced that its board has initiated a share buyback plan on Monday, May 18th that authorizes the company to buyback $5.00 billion in shares. This buyback authorization authorizes the medical equipment provider to repurchase up to 6.4% of its stock through open market purchases. Stock buyback plans are generally an indication that the company’s management believes its shares are undervalued.

Insider Activity

In related news, Director Edward J. Ludwig purchased 3,580 shares of Boston Scientific stock in a transaction dated Wednesday, May 20th. The stock was bought at an average cost of $56.68 per share, for a total transaction of $202,914.40. Following the transaction, the director owned 25,359 shares in the company, valued at approximately $1,437,348.12. The trade was a 16.44% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director David C. Habiger purchased 2,250 shares of Boston Scientific stock in a transaction dated Wednesday, May 20th. The shares were bought at an average price of $55.92 per share, with a total value of $125,820.00. Following the completion of the transaction, the director owned 13,878 shares in the company, valued at approximately $776,057.76. This trade represents a 19.35% increase in their position. The SEC filing for this purchase provides additional information. In the last three months, insiders purchased 9,800 shares of company stock worth $554,012. Company insiders own 0.34% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on BSX shares. National Bank Financial set a $115.00 target price on shares of Boston Scientific in a report on Monday, February 2nd. Argus raised shares of Boston Scientific to a “strong-buy” rating in a report on Thursday, February 26th. Mizuho reduced their target price on shares of Boston Scientific from $115.00 to $90.00 and set an “outperform” rating for the company in a report on Monday, April 13th. Morgan Stanley reduced their target price on shares of Boston Scientific from $130.00 to $118.00 and set an “overweight” rating for the company in a report on Thursday, February 5th. Finally, UBS Group reduced their target price on shares of Boston Scientific from $120.00 to $105.00 and set a “buy” rating for the company in a report on Tuesday, March 17th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, Boston Scientific has an average rating of “Moderate Buy” and an average target price of $92.71.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.